TABLE 3.
Drug susceptibility testing of Kenyan P. falciparum against a panel of antimalarial compounds
| Drug | IC50 (ng/ml) for isolates froma:
|
|||
|---|---|---|---|---|
| Entosopia (7) | Magadi (7) | Kericho (5) | Kisumu (4) | |
| Median (range) | Median (range) | Median (range) | Median (range) | |
| Quinine | 48 (27-79) | 44 (11-96) | 14 (10-17) | 56 (20-122) |
| Artemisinin | 1.0 (0.6-1.3) | 2 (0.6-2) | 1 (0.8-1) | 2 (1-2) |
| Halofantrine | 7 (.8-14) | 7 (2-10) | 0.2 (0.1-0.3) | 8 (1-20) |
| Doxycycline | 3,591 (1380-8527) | 5,303 (3120-7686) | 2,718 (1746-3670) | 6,244 (5781-6333) |
| Atovoquone | 2 (0.8-14) | 2 (0.8-3) | NTb | 0.8 (0.3-1) |
| Tafenoquine | 848 (478-1528) | 913 (813-1043) | NT | 1,046 (812-1417) |
| Amodiaquine | 10 (7-13) | 13 (8-14) | 3 (2-5) | 10 (4-13) |
| Primaquine | 656 (349-1255) | 504 (270-1276) | 416 (32-602) | 464 (289-566) |
| Dapsone | 28 (4-74) | 1,926 (60-3522) | NT | 2,804 (2345-3518) |
| Proguanil | 54 (37-86) | 905 (361-2475) | 2275 (2172-2523) | 556 (412-715) |
| Chlorcycloguanil | 3 (2-5) | 8 (1-17) | NT | 5 (2-12) |
a
Number of samples tested is given in parentheses after name of region.
b
NT, not tested.